EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study

Angela Horvath, Rosa Haller, Nicole Feldbacher, Hansjörg Habisch iD, Kristina Žukauskaitė, Tobias Madl iD, Vanessa Stadlbauer iD

Nutrients · 2024

DOI: 10.3390/nu16223970 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Angela Horvath und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria. Hauptthemen laut MEDLINE: Probiotics, COVID-19, Gastrointestinal Microbiome, Feces. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Research Promotion Agency, FWF Austrian Science Fund, Integrative Metabolism Research Center Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The novel coronavirus (SARS-CoV-2) led to gastrointestinal manifestations in up to 50% of cases, with diarrhea being common, and probiotics have been suggested as a potential treatment.

Aim

This study aimed to assess changes in the microbiome and the effects of a multispecies probiotic in patients with COVID-19 in home quarantine through a fully remote telemedical approach.

Methods

Thirty patients were randomized to receive either the Ecologic AAD probiotic (Winclove Probiotics, Amsterdam, The Netherlands), on the market as OMNi-BiOTiC 10 (Allergosan, Austria), or a placebo for 30 days in a 2:1 ratio. Respiratory and gastrointestinal symptoms were monitored in 2–10-day intervals via online surveys, and five stool samples were collected during the 30-day study period for microbiome and metabolomics analyses. Twenty-four healthy volunteers served as controls.

Results

Of the 30 patients, 26 completed this study (10 placebo, 16 probiotic). Patients reported respiratory symptoms and a diminished gastrointestinal quality of life, both of which improved significantly during the study period, irrespective of the intervention. Compared to controls, infected patients showed significant alterations in the fecal microbiome (p = 0.002), including an increase in Bacteroidetes and decreases in Christensenellaceae, Ruminococcaceae, and Gammaproteobacteria, along with metabolomic changes. Probiotic treatment significantly modulated the patients’ microbiome beta diversity (p = 0.001) and introduced the Enterococcus faecium W54 strain. Symptoms, COVID-19-related taxa, and the fecal metabolome were not affected by the intervention.

Conclusions

Patients with mild COVID-19 disease in home quarantine exhibited respiratory symptoms, a reduced gastrointestinal quality of life, and changes in the fecal microbiome and metabolome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsCOVID-19Gastrointestinal MicrobiomeFecesSARS-CoV-2Quality of LifeHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultGastrointestinal DiseasesAgedQuarantineTelemedicine

Stichwörter der Autor:innen

COVID-19Enterococcus faeciummicrobiomepatient-reported outcomesprobioticquality of life

Autor:innen und Institutionen

  • Division for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.
  • Center for Biomarker Research in Medicine (CBmed), Division Translational Precision Medicine, 8010 Graz, Austria.
  • Otto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, 8010 Graz, Austria.
  • Institute of Biosciences, Life Sciences Center, Vilnius University, 01513 Vilnius, Lithuania.
  • BioTechMed-Graz, 8010 Graz, Austria.

ORCID-Profile: Hansjörg Habisch, Tobias Madl, Vanessa Stadlbauer

Förderung

  • Austrian Research Promotion Agency
  • FWF Austrian Science Fund
  • Integrative Metabolism Research Center Graz
  • Austrian Infrastructure Program 2016/2017
  • Styrian Government (Zukunftsfonds, doc.fund program)
  • City of Graz
  • BioTechMed-Graz
  • Austrian Science Fund

Zitieren

APA

Horvath, A., Haller, R., Feldbacher, N., Habisch, H., Žukauskaitė, K., Madl, T., & Stadlbauer, V. (2024). Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study. Nutrients. https://doi.org/10.3390/nu16223970

Vancouver

Horvath A, Haller R, Feldbacher N, Habisch H, Žukauskaitė K, Madl T, et al. Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study. Nutrients. 2024. doi:10.3390/nu16223970

BibTeX
@article{Horvath2024,
  author = {Horvath, Angela and Haller, Rosa and Feldbacher, Nicole and Habisch, Hansjörg and Žukauskaitė, Kristina and Madl, Tobias and Stadlbauer, Vanessa},
  title = {Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16223970}
}
Kostenlos starten →